RAPT Q3 2020 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$15M-954.3% margin

Net Income

-$15M-957.5% margin

EPS (Diluted)

$-4.79

QoQ Revenue Growth

+19.7%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$129M

Total Liabilities

$19M

Stockholders' Equity

$110M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$15M	-$10M	-41.4%
Net Income	-$15M	-$10M	-46.7%